News & Updates

Treatment with olpasiran appears to induce a sustained and significant decrease in oxidized phospholipids associated with apolipoprotein B (OxPL-apoB) but exert no substantial effect on high-sensitivity C-reactive protein (hs-CRP) and high-sensitivity interleukin-6 (hs-IL-6), according to data from the phase II, dose-finding OCEAN(a)-DOSE trial.

In the treatment of patients with Parkinson’s disease (PD), the muscarinic acetylcholine M1 positive allosteric modulator TAK-071 falls short of improving gait, according to the results of a phase II study. However, the drug appears to be well-tolerated and have positive effect on cognition.

Initiating antihypertensive treatment with an angiotensin-converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB), or a calcium channel blocker (CCB) results in a comparable risk for myocardial infarction (MI), acute coronary syndrome (ACS), heart failure (HF), or stroke when compared with thiazides, reports a study. On the other hand, use of beta-blockers (BBs) tends to increase such risk.

In the treatment of patients with nonsevere influenza virus infection, baloxavir may reduce the risk of hospital admission and shorten the time to symptom relief, according to the results of a systematic review and meta-analysis.

Neoadjuvant radiation therapy and docetaxel prior to prostatectomy in men with localized high-risk prostate cancer has a modest toxicity profile and results in reasonable long-term outcomes, but pathologic complete response (pCR) is not achieved, results of a phase I/II trial have shown.

The melanocortin-4 receptor (MC4R) agonist setmelanotide demonstrates efficacy in the management of obesity in children younger than 6 years, according to the results of a phase III trial.

Patients with metastatic renal cell carcinoma (RCC) may gain significantly better survival outcomes with lenvatinib therapy than with other tyrosine kinase inhibitors (TKIs), suggests a study.